Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2 FLAVOR trial, a randomized, double-blinded, placebo-controlled, multi-dose clinical trial of CYR-064, its novel, soft-mist nasal-spray product candidate, for the treatment of post-viral hyposmia.
October 12, 2023
· 2 min read